We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$18.6M
Cap. Flow
+$5.56M
Cap. Flow %
1.53%
Top 10 Hldgs %
25.94%
Holding
173
New
49
Increased
12
Reduced
23
Closed
40

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$20.1M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.18M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.64M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$6.41M
5
QDEL icon
QuidelOrtho
QDEL
+$5.15M

Top Sells

Rank Stock Value
1
ALDX icon
Aldeyra Therapeutics
ALDX
+$7.59M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.09M
3
CDNA icon
CareDx
CDNA
+$5.7M
4
HAE icon
Haemonetics
HAE
+$5.22M
5
LITS
Lite Strategy Inc
LITS
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 7.92%
3 Technology 1.93%
4 Industrials 1.24%
5 Communication Services 0.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
1
DELISTED
Esperion Therapeutics
ESPR
$12.6M 3.47%
+2,515,785
New +$20.1M
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.8B
$11.8M 3.26%
346,000
– –
BLU
3
DELISTED
BELLUS Health Inc.
BLU
$11.7M 3.22%
1,450,006
-338,783
-19% -$2.25M
BCYC
4
Bicycle Therapeutics
BCYC
$275M
$10.5M 2.89%
172,000
+80,000
+87% +$4.41M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.88B
$9.4M 2.59%
331,000
+138,000
+72% +$3.4M
KDNY
6
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.89M 2.45%
545,000
+80,000
+17% +$1.14M
LNTH icon
7
Lantheus
LNTH
$6.68B
$7.86M 2.17%
272,000
-18,000
-6% -$479K
POL.WS
8
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
$7.39M 2.04%
6,103,824
-782,776
-11% -$1.03M
PEPL
9
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
$7.2M 1.99%
+735,000
New +$7.18M
KROS icon
10
Keros Therapeutics
KROS
$199M
$6.79M 1.87%
116,000
-10,000
-8% -$499K
ILMN icon
11
Illumina
ILMN
$29.2B
$6.66M 1.84%
17,990
+7,710
+75% +$2.92M
IMTX icon
12
Immatics
IMTX
$1.19B
$6.32M 1.74%
469,980
-9,007
-2% -$113K
NSTG
13
DELISTED
NanoString Technologies, Inc.
NSTG
$6.19M 1.71%
+146,500
New +$6.41M
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$5.92M 1.63%
+1,750,000
New +$6.64M
IOVA icon
15
CALL
Iovance Biotherapeutics
IOVA
$2.1B
$5.73M 1.58%
+300,000
New +$6.6M
INSM icon
16
Insmed
INSM
$22.6B
$5.54M 1.53%
203,354
– –
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.5M 1.52%
329,101
+1,000
+0.3% +$16.4K
CTIC
18
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.42M 1.49%
2,185,000
-1,128,000
-34% -$2.76M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$5.35M 1.47%
225,000
– –
INSP icon
20
Inspire Medical Systems
INSP
$1.5B
$5.29M 1.46%
23,000
-3,000
-12% -$732K
MYGN icon
21
Myriad Genetics
MYGN
$502M
$5.24M 1.45%
190,000
+32,000
+20% +$927K
QGEN icon
22
Qiagen
QGEN
$8.72B
$5.17M 1.43%
+87,704
New +$5.03M
MBTC
23
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
$5M 1.38%
500,000
– –
QDEL icon
24
QuidelOrtho
QDEL
$1.14B
$5M 1.38%
+37,000
New +$5.15M
EPIX
25
DELISTED
ESSA Pharma
EPIX
$4.9M 1.35%
+345,000
New +$3.84M
1
2 3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $42.8M AUM 49.41% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return

Altium Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Altium Capital Management held 173 positions worth $363M, down 4.9% from $381M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Altium Capital Management's Q4 2021 filing shows 49 new, 12 increased, 23 reduced and 40 closed positions. Its largest new stake was Esperion Therapeutics: 2,515,785 shares worth $12.6M. The largest sale was Aldeyra Therapeutics, an estimated $7.59M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Technology.

  • Altium Capital Management's largest Q4 2021 buy was Esperion Therapeutics: 2,515,785 shares worth $12.6M.
  • Altium Capital Management added most to Bicycle Therapeutics in Q4 2021, an estimated $4.41M increase.
  • Altium Capital Management's biggest Q4 2021 reduction was Cerus, cutting an estimated $4.27M.
  • Altium Capital Management fully exited Aldeyra Therapeutics in Q4 2021, selling an estimated $7.59M.
  • Altium Capital Management's ten largest holdings make up 26% of its $363M portfolio in Q4 2021.
  • Altium Capital Management opened 49 new positions and closed 40 in Q4 2021.
  • Altium Capital Management's portfolio value fell 4.9% quarter-over-quarter to $363M.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.